The Wealthy Venture Capitalist (or ”WVC”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech and pharma stocks making news and subsequent market moves, would like to update investors on several new advancements in cancer therapies.
The United States is one of the most challenging jurisdictions in the world when it comes to intellectual property, and for many reasons the US Patent and Trademark Organization is one of the most important government bodies in the world from a market perspective. The USPTO has never been easy to deal with, and they tightly monitor substances that companies attempt to patent.
Recently Propanc Biopharma, Inc. (OTC: PPCB) has been getting good news from the US gatekeepers when the USPTO recognized that the composition of its lead drug PRP, which is a solution of two proenzymes, trypsinogen and chymotrypsinogen was unexpected and novel, and that someone ordinarily skilled in the art wouldn’t have discovered the combination that Propanc has achieved. In achieving this, Propanc has nearly patented the unpatentable, pushing forward with composition claims that constitute the highest level of protection a company can attain for any invention, particularly drugs for human use.
Propanc’s sixty-five patents in force or pending around the world different feature ratios of its two key proenzymes, and the company has put forward defensive IP filings around other combinations that tie in synergistic and additive effects related to its flagship proenzymes. Propanc is also moving to protect the chemical relationship between its creations and other ingredients that could use in work in unison with the proenzymes to enhance its antitumor effects. Propanc is also making headway in its ability to further define and quantify the uniqueness and effectiveness of PRP through a proprietary bio-analytical assay process.
Propanc’s business and scientific team are working to take hold of the field of proenzymes being used to treat cancer as a new therapeutic approach to preventing occurrence and metastatic cancer. Heading into clinical trials this IP protection is of utmost importance, along with the bioanalytical assay process, especially if they can get positive human data. The company’s strong IP position puts it in a good position to move forward.
Propanc has gotten an S1 equity line of credit approved through the SEC with a no review, and its work on a reverse split with a 14C filing did not draw comments. The company’s overall goals are further capital funding to clinical trial application stage further funding for clinical development of PRP.
GTx, Inc. (NASDAQ: GTXI) is a public company that engages in small molecule development for cancer and other conditions but is set to merge with a privately held company, showing the difficulty of carving out unique territory in the cancer space. ImmunoGen, Inc. (NASDAQ: IMGN) is an example of a company that is shedding market cap fast as development news does not seem to be coming in positively. IMGN shares dropped hard in late February. Sesen Bio, Inc. (NASDAQ: SESN) has seen institutional investors beef up holdings recently, hoping for positive news in late-stage drug development based on its Targeted Protein Therapeutics (TPTs) platform.
The Wealthy Venture Capitalist is a series of industry-focused investment articles focused on showing everyday Investors new opportunities in rapidly growing, little-known stocks in 4 of the markets hottest sectors.
Sign up for Alerts
Sign up for text message alerts: http://clk2.it/k7oF5z
Email newsletter sign up: http://wealthyventurecapitalist.com/newsletter/
Follow The Wealthy Venture Capitalist on Social Media
This report/release/profile is a commercial advertisement and is for general information and entertainment purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Venture Capitalist and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Venture Capitalist encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Venture Capitalist makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be ”forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as ”projects”, ”foresee”, ”expects”, ”will”, ”anticipates”, ”estimates”, ”believes”, ”understands”, or that by statements indicating certain actions ”may”, ”could”, or ”might” occur. Understand there is no guarantee past performance will be indicative of future results.
The Wealthy Venture Capitalist’s parent company has been, and will be, compensated an average of $6,500 per month over a 1-year contract by Propanc Health Group. We have also been compensated 8 million restricted common shares of Propanc Health Group by the Company, and will sell these shares into the market as soon as the 144 hold period has lapsed.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.